Background: The contact factor XII (FXII) activates upon contact with a variety of
| INTRODUCTION
Blood-contacting medical devices, including catheters, stents, grafts, filters, and extracorporeal organ support (ECOS) systems can fail due to thrombus accumulation in the system and may also trigger deviceassociated thromboembolism.
1 To maintain patency, devices that are perfused for various lengths of time require prophylactic anticoagulation, which can increase the incidence and/or severity of bleeding.
Inhibiting the blood coagulation contact activation pathway has been proposed as an alternative approach to safer anticoagulation. [2] [3] [4] Extracorporeal membrane oxygenation (ECMO) is an ECOS system that has been increasingly used for short-term management of acute respiratory failure, such as in cases of complicated influenza, or in the temporal alleviation of acute heart failure; however, its benefits are reduced by anticoagulation-associated bleeding. [5] [6] [7] ECMO systems have several components that promote the activation of platelets and the blood coagulation contact system, including the hollow fibers and membranes that are exposed to flowing blood.
8
Activation of the coagulation cascade in vivo leads to thrombin generation, platelet activation, and subsequent fibrin formation to support both hemostasis and pathological vaso-occlusive thrombosis/ thromboembolism. 9 Pharmacological thromboprophylaxis can be effectively achieved with existing antithrombotics; however, these currently available treatments also cause bleeding since they inhibit key hemostatic plasma proteins such as thrombin or activated coagulation factor Xa (FXa). 10, 11 Accordingly, these drugs cannot be dosed to full efficacy due to dose-limiting antihemostatic toxicity, and thus thrombotic vessel occlusion remains the leading cause of mortality in industrialized countries. 12 To address the issue of antithrombotic safety, we proposed that inhibiting contact system activation would be a safer alternative to current antithrombotic therapy. 2 Steadily increasing efforts are under way in both industry and academia to develop inhibitors to members of the contact activation complex to improve the safety of therapeutic and prophylactic anticoagulation. 13 The plasma contact activation complex, which includes FXII, prekallikrein (PK), and high-molecular-weight kininogen (HK), has been shown to promote pathological thrombus formation. This complex is activated following exposure of blood to negatively charged surfaces, including a variety of biological molecules and artificial materials. 4, 14, 15 FXII is a key member of this pathway, with a plasma concentration of 30-40 µg/mL (375-500 nM). 16 Surface-catalyzed cleavage of FXII, an 80-kDa single-chain zymogen, after Arg353
generates the protease α-FXIIa. Cleavage of α-FXIIa after Arg334 generates β-FXIIa, which is comprised of the FXIIa catalytic domain. α-FXIIa activates factor XI (FXI) to FXIa and ultimately leads to thrombin (factor IIa [FIIa]) generation. Concomitantly, α-FXIIa activates the zymogen PK to α-kallikrein, which then converts additional FXII to α-FXIIa. β-FXIIa can activate components of the complement system and as part of the kallikrein-kinin system cleaves the cofactor HK to liberate the potent systemic vasoregulatory and proinflammatory molecule bradykinin. 17 Thus, contact activation initiates both prothrombotic and proinflammatory processes.
18
Contact activation of plasma drives thrombin formation in the activated partial thromboplastin time (aPTT) assay in vitro. Plasma samples from mammals lacking any of the contact system proteins have prolonged aPTTs, yet aPTT prolongation is not diagnostic of hemostasis impairment. 19 Although hereditary FXI deficiency produces an aPTT prolongation and can cause a mild bleeding disorder (hemophilia C), deficiency of FXII, PK, or HK all result in aPTT prolongation but remain asymptomatic. [20] [21] [22] Importantly, while playing a minor to no role in hemostasis, these proteins appear to contribute significantly to thrombosis in experimental animal models. [23] [24] [25] FXIIa inhibition using the anti-FXIIa antibody 3F7 in a rabbit model of ECMO reduced fibrin deposition in the oxygenator without evidence of increased bleeding. [26] [27] [28] Since platelets are critical to the formation of occlusive thrombi, here we extended this approach using a potent new anti-FXII monoclonal antibody, and show that FXII inhibition also reduces platelet activation and deposition within membrane oxygenators in both heparinized and nonheparinized nonhuman primates. 
| MATERIALS AND METHODS

| Generation of anti-FXII monoclonal antibodies
| Characterization of 5C12
To measure aPTT prolongation, one-tenth volume of 200 µg/mL of purified 5C12 stock (0.13 µM final concentration in plasma) or phosphate buffered saline (PBS) vehicle pH 7.4 was incubated for 3 minutes with human or baboon platelet-poor plasma that was serially diluted with FXII-deficient plasma (Affinity Biologicals, Ancaster, Ontario, Canada) to yield an FXII concentration range in plasma and keeping the antibody concentration constant. In the second set of aPTT experiments, the concentration of 5C12 was varied (0-4 µM) and tested in normal baboon or human plasma and also compared to the FXIIa inhibitor, corn trypsin inhibitor (CTI). 5C12 was also used as the primary antibody in western blots to detect FXII in human and baboon plasma, as well as purified α-and β-FXIIa. 
| Anticoagulation of baboons
In an initial dose-finding experiment, 6 consecutive 5C12 doses 
| Hemostasis assessment
| Blood sample analyses
Blood samples were collected into citrate and plasma aPTT was 
| Flow chamber analysis
Glass capillary tubes (0.2 × 2×200 mm; Vitrocom, Mountain Lakes, NJ, USA) were coated with 100 µg/mL of fibrillar type I collagen (Chrono-Log Corp, Havertown, PA, USA) in the absence or in combination with 0.1-nM tissue factor (Dade Innovin, Siemens, Flanders, NJ, USA) for 1 hour at room temperature (RT). Capillaries were washed with PBS and then blocked with 5 mg/mL denatured bovine serum albumin for 1 hour at RT before connecting them to a syringe pump and a blood reservoir. Human venous blood was drawn by venipuncture into syringes containing 3.8% (w/v) sodium citrate (one-tenth of blood volume) in the absence or presence of 100 µg/mL 5C12; blood was recalcified prior to perfusion as previously described. 36 After blood perfusion, capillaries were washed with PBS, fixed with 4% paraformaldehyde, and sealed with Fluoromount G. Platelet aggregates and fibrin formation in the capillaries were then imaged for analysis using a 63 × Zeiss Axio Imager M2 microscope as described. CA, USA). For differences between means, a probability of < 0.05 was considered statistically significant.
| RESULTS
| Characterization of 5C12
Initial experiments were designed to validate the role of FXII in ini- 
| Characterization of the anticoagulant activity of 5C12 in vivo
We next tested the antibody in a single juvenile baboon. 5C12 was administered in a stepwise manner consisting of 6 doses of 1 mg/kg given 40 minutes apart. Our results show that 5C12 caused a nearly 3-fold increase in the plasma aPTT from baseline after the second dose; a 4-fold increase in aPTT above baseline was recorded after the fifth dose ( Figure 3A) . A corresponding increase in ACT was recorded ( Figure 3B ). As expected, 5C12 did not affect prothrombin time or baseline circulating TAT levels or blood cell counts ( Figure 3C -H).
| Effect of 5C12 on thrombus formation under flow
Experiments were designed to determine the effect of inhibiting A change in template bleeding time for all treatment groups, including heparin, was not observed for any of the groups tested ( Figure 5E ).
| Effect of 5C12 on systemic markers of coagulation
Blood samples taken at the beginning and end of each oxygenator perfusion experiment were analyzed for markers of thrombin generation (TAT levels) and platelet activation (PF4 levels) (Figure 6 ), while levels of anticoagulation were assessed by measuring the aPTT, ACT, and PT at the 0-and 60-minute time points. A robust increase in systemic levels of TAT and PF4 were observed at the end of the 60 minutes of oxygenator perfusion in the absence of any anticoagulant.
Pretreatment of the baboons with 5C12 either alone or in combination with low-dose heparin resulted in a significant reduction in both TAT and PF4 levels ( Figure 6A-B) . A corresponding increase in aPTT and ACT was observed for both cohorts, while the PT was unaffected by 5C12 alone ( Table 1 ). The study was underpowered to draw a conclusion regarding the effect of low-dose heparin alone on TAT and PF4 levels compared to no treatment; we did confirm that low-dose heparin caused an increase in aPTT, ACT, and PT as compared to baseline (Table 1) .
| DISCUSSION
In this study, we demonstrate that intravenous administration of the newly described anti-FXII monoclonal antibody, 5C12, signifi- Moreover, it is also possible that the reagents used in the aPTT assay induce enzymatic reactions that are contact initiated but not entirely F I G U R E 4 Effect of 5C12 on fibrin and thrombus formation on surfaces coated with collagen and/or tissue factor in vivo (A-D) or in vitro (E-H). Expanded polytetrafluoroethylene grafts (4 mm i.d., 20 mm long) were coated with collagen (A, B) or tissue factor (C, D) and inserted into the external loop of a chronic AV shunt of a baboon. Platelet deposition (A, C) and fibrin content (B, D) was measured (n = 3 for vehicle, n = 6 for h5C12). Administration of 9 mg/kg h5C12 given 1-24 hours before significantly reduced both platelet and fibrin accumulation on collagen but not tissue factor. Microfluidic glass capillaries coated with 100 µg/mL collagen alone (E, F) or in the presence of 0.1 nM tissue factor (G, H). 100 µg/ mL 5C12 blocked fibrin formation on collagen alone but did not affect thrombus formation on collagen and tissue factor. Representative images from n > 3 experiments; data represents mean ± SEM from n = 3-6; **P < 0.01 vs vehicle FXII facilitates embryo implantation 42, 43 , promotes tissue repair, angiogenesis, and mitogenesis 44 ; enhances vasodilation and inflammation through kallikrein activation and bradykinin generation 45 ; may contribute to autoimmune disease pathogenesis through dendritic cell interactions 46 ; and FXII produced by neutrophils appears to play a role in normal neutrophil function. 47 Despite all of these data, pathology has not been associated with FXII deficiency, suggesting it could be a safe drug target. Since the existence and roles of potential adaptive mechanisms have not been described in Abbreviations: ACT, activated clotting time; aPTT, activated partial thromboplastin time; ECMO, extracorporeal membrane oxygenation; PT, prothrombin time.
